BioCentury
ARTICLE | Strategy

Will the tarnish rub off?

June 1, 1998 7:00 AM UTC

OXFORD - As the dust begins to settle on British Biotech plc's fall from grace, the implications of what this means for the company, its executives past and present, and the U.K. and continental European sectors are only beginning to emerge.

So far, BBG would have to be mistaken if it thought that CEO Keith McCullagh falling on his sword while the company published its rebuttal of allegations surrounding the conduct of clinical trials, the company's strategy and the sacking of clinical director Andrew Millar was going to put a lid on the controversy...